Literature DB >> 32712959

First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia.

Stephen Dong1, Tarek Khedro1, Pamela Ward2, Louis Dubeau2, Bassam Yaghmour3, Imran Siddiqi2, George Yaghmour1.   

Abstract

Entities:  

Keywords:  BRAF V600E mutation; T-cell prolymphocytic leukemia; dasatinib; vemurafenib; venetoclax (BCL-2 inhibitor)

Mesh：

Substances：

Year:  2020        PMID： 32712959      PMCID： PMC9007147          DOI： 10.1111/bjh.16992

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  14 in total

1.  Bendamustine is effective in T-cell prolymphocytic leukaemia.

Authors:  Charles Herbaux; Philippe Genet; Krimo Bouabdallah; Jean-Michel Pignon; Houria Debarri; Stéphanie Guidez; Sarah Betrian; Xavier Leleu; Thierry Facon; Franck Morschhauser; Gandhi Damaj; Bruno Cazin; Loïc Ysebaert
Journal:  Br J Haematol       Date:  2014-10-15       Impact factor: 6.998

Review 2.  Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Authors:  Philipp B Staber; Marco Herling; Mar Bellido; Eric D Jacobsen; Matthew S Davids; Tapan Mahendra Kadia; Andrei Shustov; Olivier Tournilhac; Emmanuel Bachy; Francesco Zaja; Kimmo Porkka; Gregor Hoermann; Ingrid Simonitsch-Klupp; Claudia Haferlach; Stefan Kubicek; Marius E Mayerhoefer; Georg Hopfinger; Ulrich Jaeger; Claire Dearden
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

3.  Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.

Authors:  Cristina López; Anke K Bergmann; Ulrike Paul; Eva M Murga Penas; Inga Nagel; Matthew J Betts; Patricia Johansson; Matthias Ritgen; Tycho Baumann; Marta Aymerich; Sandrine Jayne; Robert B Russell; Elias Campo; Martin J S Dyer; Jan Dürig; Reiner Siebert
Journal:  Br J Haematol       Date:  2016-02-25       Impact factor: 6.998

4.  A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).

Authors:  Chandrayee Ghosh; Suresh Kumar; Yevgeniya Kushchayeva; Kelli Gaskins; Myriem Boufraqech; Darmood Wei; Sudheer Kumar Gara; Lisa Zhang; Ya-Qin Zhang; Min Shen; Sanjit Mukherjee; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2020-01-14       Impact factor: 12.531

5.  Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Authors:  Alexandra Gomez-Arteaga; Elizabeth Margolskee; Mike T Wei; Koen van Besien; Giorgio Inghirami; Steven Horwitz
Journal:  Leuk Lymphoma       Date:  2019-04-18

6.  Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.

Authors:  Mark J Kiel; Thirunavukkarasu Velusamy; Delphine Rolland; Anagh A Sahasrabuddhe; Fuzon Chung; Nathanael G Bailey; Alexandra Schrader; Bo Li; Jun Z Li; Ayse B Ozel; Bryan L Betz; Roberto N Miranda; L Jeffrey Medeiros; Lili Zhao; Marco Herling; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Blood       Date:  2014-05-13       Impact factor: 22.113

7.  First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Authors:  Bernd Boidol; Christoph Kornauth; Emiel van der Kouwe; Nicole Prutsch; Lukas Kazianka; Sinan Gültekin; Gregor Hoermann; Marius E Mayerhoefer; Georg Hopfinger; Alexander Hauswirth; Michael Panny; Marie-Bernadette Aretin; Bernadette Hilgarth; Wolfgang R Sperr; Peter Valent; Ingrid Simonitsch-Klupp; Richard Moriggl; Olaf Merkel; Lukas Kenner; Ulrich Jäger; Stefan Kubicek; Philipp B Staber
Journal:  Blood       Date:  2017-09-27       Impact factor: 22.113

8.  SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.

Authors:  Patricia Johansson; Ludger Klein-Hitpass; Axel Choidas; Peter Habenberger; Bijan Mahboubi; Baek Kim; Anke Bergmann; René Scholtysik; Martina Brauser; Anna Lollies; Reiner Siebert; Thorsten Zenz; Ulrich Dührsen; Ralf Küppers; Jan Dürig
Journal:  Blood Cancer J       Date:  2018-01-19       Impact factor: 11.037

9.  JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.

Authors:  Linus Wahnschaffe; Till Braun; Sanna Timonen; Anil K Giri; Alexandra Schrader; Prerana Wagle; Henrikki Almusa; Patricia Johansson; Dorine Bellanger; Cristina López; Claudia Haferlach; Marc-Henri Stern; Jan Dürig; Reiner Siebert; Satu Mustjoki; Tero Aittokallio; Marco Herling
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

10.  Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies.

Authors:  Allison Greenplate; Kai Wang; Rati M Tripathi; Norma Palma; Siraj M Ali; Phil J Stephens; Vincent A Miller; Yu Shyr; Yan Guo; Nishitha M Reddy; Lina Kozhaya; Derya Unutmaz; Xueyan Chen; Jonathan M Irish; Utpal P Davé
Journal:  JCO Precis Oncol       Date:  2018-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.